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Alzheimer’s disease (AD) is defined by the presence of intraneuronal neurofibrillary
tangles (NFTs) composed of hyperphosphorylated tau aggregates as well as extracellular
amyloid-beta plaques. The presence and spread of tau pathology through the brain is
classified by Braak stages and thought to correlate with the progression of AD. Several
in vitro and in vivo studies have examined the ability of tau pathology to move from
one neuron to the next, suggesting a “prion-like” spread of tau aggregates may be an
underlying cause of Braak tau staging in AD. Using the HEK293 TauRD-P301S-CFP/YFP
expressing biosensor cells as a highly sensitive and specific tool to identify the presence
of seed competent aggregated tau in brain lysate—i.e., tau aggregates that are capable
of recruiting and misfolding monomeric tau—, we detected substantial tau seeding levels
in the entorhinal cortex from human cases with only very rare NFTs, suggesting that
soluble tau aggregates can exist prior to the development of overt tau pathology. We
next looked at tau seeding levels in human brains of varying Braak stages along six
regions of the Braak Tau Pathway. Tau seeding levels were detected not only in the brain
regions impacted by pathology, but also in the subsequent non-pathology containing
region along the Braak pathway. These data imply that pathogenic tau aggregates
precede overt tau pathology in a manner that is consistent with transneuronal spread
of tau aggregates. We then detected tau seeding in frontal white matter tracts and the
optic nerve, two brain regions comprised of axons that contain little to no neuronal cell
bodies, implying that tau aggregates can indeed traverse along axons. Finally, we isolated
cytosolic and synaptosome fractions along the Braak Tau Pathway from brains of varying
Braak stages. Phosphorylated and seed competent tau was significantly enriched in the
synaptic fraction of brain regions that did not have extensive cellular tau pathology, further
suggesting that aggregated tau seeds move through the human brain along synaptically
connected neurons. Together, these data provide further evidence that the spread of tau
aggregates through the human brain along synaptically connected networks results in
the pathogenesis of human Alzheimer’s disease.
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INTRODUCTION
Primary tauopathies encompass a major class of
neurodegeneration that is defined by those neurological disorders
containing intracellular accumulations of the microtubule-
associated protein tau. Of the primary tauopathies that exist,
Alzheimer’s disease (AD) is the most common. In addition
to intraneuronal neurofibrillary tangles (NFTs) composed of
hyperphosphorylated tau aggregates, extracellular plaques that
result from the accumulation of the amyloid-beta peptide are a
prominent pathology in the AD brain (Hyman et al., 1984; Braak
and Braak, 1991). While both of these pathological hallmarks are
required for the classification of AD, there appears to be a more
direct correlation between the accumulation of tau pathology
and cognitive decline (Arriagada et al., 1992; Zhou et al., 2012;
Xia et al., 2017).
One of the major contributions to the idea of tau pathology
spreading through the brain in a “prion-like” manner is the
observation made by Braak and Braak, whereby tau pathology
manifests in a consistent spatiotemporal pattern in human AD
brains (Braak and Braak, 1991). It has been hypothesized this
pattern suggests a transneuronal propagation of tau aggregates
from one brain region to the next. In vitro studies have observed
the ability of tau aggregates to move along axons and dendrites
in neuronal cultures, both antero- and retrograde, as well as
the ability of tau aggregates to leave one neuron and be taken
up by another (Wu et al., 2013; Calafate et al., 2015; Takeda
et al., 2015). In vitro studies have further demonstrated the
ability of tau aggregates to behave similar to prions in that they
possess the ability to recruit and ultimately template the naïve
monomeric version of the protein. Building on this in vitro work,
in vivo models have been generated to better study this “prion-
like” propagation of tau pathology along synaptically connected
networks in the intact brain. Aggregates of tau injected into
mouse brains appear to move from the site of injection to
synaptically connected regions (Clavaguera et al., 2013; Iba et al.,
2013; Sanders et al., 2014; Calafate et al., 2015; Kaufman et al.,
2017; Narasimhan et al., 2017). Further, when human tau is
expressed selectively in the entorhinal cortex, it has been shown
to propagate to the adjoining dentate gyrus of the hippocampus,
suggesting that tau pathology is capable of traversing neural
networks in the living brain (de Calignon et al., 2012; Liu et al.,
2012).
This phenomenon of tau propagation in the human brain
has thus far been based almost exclusively on cross-sectional
staining for tau pathology in post-mortem tissue at different
points in AD disease progression. As tau imaging markers have
evolved, additional studies have been performed looking at the
deposition of tau pathology in association with brain atrophy
using positron emission tomography (PET) in living patients,
finding that the formation of tau pathology—as defined by tau
PET ligand binding—occurs along the immunohistologically
described Braak Tau Pathway and directly correlates with
neuronal dysfunction and ultimately loss (Ishiki et al., 2015;
Ossenkoppele et al., 2016; Schöll et al., 2016; Sepulcre et al.,
2016; Hoenig et al., 2018; Iaccarino et al., 2018). These studies
demonstrate that NFTs systematically form first in layer 2 of the
entorhinal cortex and, from there, progress to the hippocampal
formation, posterior parahippocampal gyrus, anterior cingulate
cortex, visual association area, and ultimately culminate in the
primary visual cortex. Similar to what has been observed in
tau transgenic mice (Holmes et al., 2014), tau “seeding”—the
ability of tau aggregates to recruit and misfold naïve monomeric
tau—can be detected prior to the development of overt tau
pathology in human AD brains (Furman et al., 2017). We
sought to expand on these results and test tau seeding levels
along the Braak Tau Pathway. In addition to measuring tau
seeding in cortical gray matter regions where neuronal cell bodies
and NFTs are abundant, we examined tau seeding in (1) the
axons by looking at the frontal white matter tracts and optic
nerve and (2) the synapses by isolating synaptosomes from
different regions along the Braak Tau Pathway in an effort to
determine if aggregated tau can traverse neural networks through
transneuronal propagation in the human AD brain. Together,
these experiments add to the growing body of evidence that tau
aggregates capable of corrupting naïve tau can move through the
human brain along synaptically connected neuronal networks,
resulting in the progression of AD.
MATERIALS AND METHODS
Human Post-mortem Brain Collection
Human tissue samples were obtained from the Massachusetts
Alzheimer’s Disease Research Center Neuropathology Core
at the MassGeneral Institute for Neurodegenerative Disease
(Table 1). All brains were initially sliced coronally at the time
of autopsy and immediately flash frozen between metal plates
on dry ice. All brain sections were stored at −80◦C. At the
time of collection, approximately 1-cm of the desired brain
region was dissected out of the frozen brain section and
kept at −80◦C until homogenization. To test for tau seeding
along the Braak Tau Pathway, the following brain regions
were collected under the guidance of a MGH neuropathologist
from 29 human patients ranging from Braak I—Braak VI:
Entorhinal cortex, Hippocampus, Posterior Parahippocampal
Gyrus, Anterior Cingulate, Visual Association Area, Primary
Visual Cortex, and Cerebellar Vermis. All cases had been
formerly examined by an MGH neuropathologist to generate a
neuropathological diagnosis. Additionally, all cases were blindly
assessed for (1) the density of neuritic beta amyloid plaques
based on a scoring system developed by the Consortium to
Establish a Registry for Alzheimer’s disease (Morris et al., 1989),
(2) the distribution of beta amyloid plaques (Thal score) (Thal
et al., 2002), and (3) the Braak tau stage based on the location
of neurofibrillary tau tangles as determined by a total tau
immunostaining and Bielchowsky’s silver stain (Braak and Braak,
1991). These three scores were used to generate an Alzheimer’s
disease neuropathologic change (ADNC) rating or “ABC score”
(Hyman et al., 2012).
Immunohistochemistry
The contralateral hemisphere of all cases that had sections
obtained for biochemical analysis was post-fixed in formalin.
Brain regions of interest were paraffin-embedded and cut
into 8µm thick tissue sections and subsequently mounted on
slides. All sections were de-paraffinized with xylene followed
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TABLE 1 | Human demographics and neuropathological data.
Case # Age at death PMI NPDX Braak ADNC CERAD Figure
A B C
2064 50–55 14 FTD 0 0 0 0 0 4
2065 66–70 49 FTD 0 0 0 0 0 4
2067 60–65 46 ALS 0 0 0 0 0 4
2075 46–50 38 ALS 0 0 0 0 0 4
1841 66–70 12 Superficial Siderosis I 1 1 1 A possible 3
1893 80–85 14 CVD I 2 1 1 A possible 3
1928 >90 18 CVD I 0 1 n/a 0 1, 3, 4
1965 76–80 48 Control I 1 1 1 A possible 3, 5
2038 76–80 6 Control I 0 1 0 0 4
2041 70–75 24 PD I 0 n/a n/a n/a 4
1872 >90 22 CVD II 3 1 1 A possible 1, 3, 4
1504 75–80 12 DLB II n/a 2 1 A possible 3
1755 80–85 6 PD II n/a 1 n/a n/a 3, 5
1777 86–90 24 AD II 0 1 0 0 3, 5
1900 86–90 16 LBD II 3 1 2 B probable 3
1972 66–70 23 PD II 2 1 1 A possible 3, 5
2068 76–80 9 Control II 0 0 1 0 4
1759 60–65 12 DLB, AD III 2 2 2 B probable 3
1854 80–85 6 AD III 1 2 1 A possible 3, 5
1876 >90 18 AD III 3 2 2 B probable 3
1899 86–90 14 AD III 3 n/a n/a B probable 3
1907 86–90 14 AD III 1 n/a n/a A possible 3, 5
1946 86–90 14 Control III 0 2 n/a 0 3
1968 86-90 10 AD III 3 2 2 B probable 3, 5
1516 >90 16 AD IV n/a 1 1 A possible 3
1820 80–85 20 AD IV 3 3 3 C definite 3
1827 86–90 5 AD IV 3 3 2 B probable 3
1970 86–90 16 AD IV 2 3 2 B probable 3
2040 >90 23 AD IV 3 2 1 A possible 4
1906 70–75 12 AD V 3 2 2 B probable 3
1926 80–85 6 AD V 3 3 2 B probable 3
1948 66–70 18 AD V n/a n/a n/a B probable 3, 5
1963 76–80 15 AD V 3 3 2 B probable 3, 5
1971 76–80 22 AD V 3 3 2 B probable 3
1987 76–80 7 AD V 3 3 3 C definite 3, 5
2019 80–85 12 AD V 3 3 3 C definite 4
2021 80–85 24 AD V 3 3 2 B probable 4
1810 76–80 7 AD VI 3 3 3 C definite 3, S2
1845 >90 19 AD VI 3 3 3 C definite 3, 5
2023 80–85 n/a AD VI 3 3 3 C definite 1, 4, S2
2026 >90 12 AD VI 3 3 3 C definite 4
2037 70–75 22 AD VI 3 3 3 C definite 4
2039 70–75 24 AD VI 3 3 3 C definite 4
2056 >90 9 AD VI 3 3 3 C definite 1, 4, S2
2057 80–85 39 AD VI 3 3 2 B probable 4
2066 86–90 24 AD VI 3 3 3 C definite 1, 4, S2
2069 86–90 12 AD VI 3 3 3 C definite 1, 4, S2
AD, Alzheimer’s Disease; PD, Parkinson’s Disease; FTD, Frontotemporal Dementia; ALS, Amyotrophic Lateral Sclerosis; DLB, Dementia with Lewy Body Disease; CVD, Cerebrovascular
Disease; ADNC, Alzheimer’s Disease Neurological Changes; NPDX, Neuropathologic diagnosis; PMI, Post-mortem interval.
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by a descending ethanol series. Slides were incubated in 3%
H2O2 immediately prior to immunolabeling. For the Aβ stain,
sections were first incubated with 90% formic acid for 5min.
All sections were then rinsed with TBS and incubated with
either 1:3,000 rabbit polyclonal anti-tau (DAKO) or 1:200
mouse monoclonal anti-amyloid beta (Clone 6F/3D, DAKO) for
1 h at room temperature. Immunolabeling was then visualized
using Vectastain rabbit or mouse IgG horse-radish peroxidase
(HRP) kits (VectorLabs) and Vector peroxidase substrate kit
DAB (VectorLabs). Slides were then dehydrated in ascending
ethanol/xylene and coverslipped with Cytoseal XL. For the
Bielschowsky silver stain, sections were prepared the same as
above and de-paraffinized with xylene followed by a descending
ethanol series. Slides were incubated with 20% silver nitrate
(diluted in distilled water) for 15min in the dark, silver
nitrate solution set aside, and slides washed once with distilled
water. The saved silver nitrate was titrated with concentrated
ammonium hydroxide until the precipitate disappeared and
slides then incubated with this ammoniated silver nitrate solution
in the dark for 10min. The ammoniated silver nitrate solution
was removed and set aside. Slides were washed in ammonia water
(1mL concentrated ammonium hydroxide in 1 L distilled water)
for 1min followed by 1min in distilled water. 0.5mL developer
solution (20mL 10% formalin, 0.5 g citric acid, 100mL distilled
water, 1 drop concentrated nitric acid) was added to 100mL
ammoniated silver nitrate and added to washed slides. Slides were
incubated 0.5–6min, or until turned light brown. Slides washed
1 × 1min in ammonia water followed by 4x washes distilled
water. Slides were then dehydrated in ascending ethanol/xylene
and coverslipped with Cytoseal XL. Sections were imaged using
brightfield at 20X on the Olympus NanoZoomer 2.0-HT slide
scanner (Hamamatsu).
Tissue Homogenization
Frozen human tissue was placed on wet ice until just thawed
and then immediately placed in 500 µL of PBS + protease
inhibitor (Roche) in a 2mL glass dounce homogenizer. Tissue
was dounce homogenized with 30 up/down strokes on ice by
hand. The homogenate was transfer to a 1.5mL Eppendorf tube
and centrifuged at 3,000 × g for 10min at 4◦C. The supernatant
was collected and aliquoted so that no sample was frozen/thawed
more than three times. A bicinchoninic acid assay (BCA, Thermo
Scientific Pierce) was performed to determine total protein
concentration.
SDS-PAGE and Western Blot
Ten to thirty micrograms of total protein per well was
loaded on 4–12% Bis-Tris SDS-PAGE gels (Invitrogen) and
run in MES buffer (Invitrogen). Proteins were transferred to
Immobilon polyvinylidene fluoride membrane (PVDF) (EMD
Millipore) and incubated overnight at 4◦C with primary
antibodies anti-rabbit polyclonal total tau (1:2,000, DAKO), anti-
mouse monoclonal phospho-tau PHF-1 (1:2,000, gift from Peter
Davies), anti-chicken GAPDH (1:2,000, Abcam), anti-rabbit
NeuN (1:1,000, Cell Signaling), anti-mouse PSD-95 (1:1,000,
Abcam), anti-chicken beta-tubulin (1:1,000, Aves Labs), or
anti-rabbit actin (1:1,000, Abcam) in 1:1 Odyssey blocking
buffer:distilled water. Blots were washed 3x 10min in Tris
buffered saline + 0.25% Tween (TBS-T) the next day, incubated
with infrared secondary anti-mouse 800, anti-rabbit 680, or anti-
chicken 800 (1:2,000, Licor) antibodies in blocking buffer for 1.5 h
at room temperature, washed 3x 10min in TBS-T, and imaged
on an Odyssey Infrared Imaging System (Licor). Blots were
converted to grayscale and densitometry analysis was performed
in ImageJ (NIH v1.51n). For the synaptosome and cytosolic
western blots, the PHF1:Total tau ratio was calculated by taking
the densitometry value for PHF1 and dividing it by the total tau
densitometry value.
Enzyme-Linked Immunosorbent Assay
(ELISA)
The ELISA was performed using 3,000 × g PBS soluble lysate.
Total tau was measured using the Meso Scale Diagnostics (MSD)
total human tau ELISA (MSD) and the manufacturer’s protocol
was followed. Plates were developed using the MESO QuickPlex
SQ 120 Plate Reader (MSD). Samples were run in triplicate and
fit to an eight-point standard curve for total tau concentration
determination.
In Vitro Tau Seeding Activity
In vitro tau seeding activity was assessed as previously described
(Holmes et al., 2014; Furman et al., 2015). HEK293 cells stably
expressing the repeat domain of Tau with the P301S mutation
(Tau-RDP301S) fused with cyan fluorescent protein (CFP) and
yellow fluorescent protein (YFP) were plated in poly-D-lysine
treated 96-well clear bottom plates (Corning) at 30,000 cells/well.
The following day when cells were at 60–70% confluency, cells
were transduced with 1.0 µg/well lysate plus 1% Lipofectamine
2000 (Invitrogen) diluted in OptiMEM (Thermo Fisher). For
the total tau normalization seeding study, 50 µL of 40 ng/mL
total tau was used. Each lysate was applied in triplicate. Cells
were exposed to lysate for 20–24 h. At the time of collection,
cells were trypsinized and transferred to 96-well U-bottom plates
(Corning) using chilled DMEM + 10% fetal bovine serum (FBS)
to inhibit the activity of the trypsin. Cells were pelleted at 1,000
xg, resuspended in freshly-made 2% paraformaldehyde (PFA)
(Electron Microscopy Services) for 10min at room temperature
in the dark, and pelleted at 1,000 × g. Cells were resuspended
in chilled PBS and run on the MACSQuant VYB (Miltenyi) flow
cytometer. CFP and Forster resonance energy transfer (FRET)
were both measured by exciting the cells using the 405 nm laser
and reading fluorescence emission at the 405/50 and 525/50 nm
filters, respectively. To quantify the FRET signal, a bivariate
plot of FRET vs. the CFP donor was generated and cells that
received lipofectamine alone were used to identify the FRET-
negative population. Using this gate, the “tau seeding” value
was calculated by multiplying the percent of FRET-positive
cells by the median fluorescence intensity of that FRET-positive
population. 40,000 cells per well were analyzed. Data was
analyzed using the MACSQuantify software (Miltenyi). Four
carry-over samples were used for each plate to normalize across
multiple plates run at the same time. Immediately prior to
collection, representative images of HEK293 cells with aggregates
were taken using the ZOE Fluorescent Cell Imager (BioRad)
using the green fluorescent protein (GFP) channel.
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Synaptosome and Cytosol Preparation
The Synaptosome (SYN) and cytosolic (CYT) fractions were
prepared as previously described (Tai et al., 2012; Jhou and Tai,
2017), with minor modifications. See Supplementary Figure 1
for the protocol schematic and conditions tested. 200mg of
frozen human brain was gently homogenized with 25 strokes
on ice in a Potter-Elvehjem homogenizer in chilled 500 µL of
Buffer A (25mMHEPES pH7.5, 120mMNaCl, 5mMKCl, 1mM
MgCl2, 2mM CaCl2) supplemented with 1mM DTT and 1X
protease inhibitor (Roche) in a 2mL glass dounce homogenizer.
The homogenate plus 600 µL Buffer A was then passed through
2 layers of Millipore Nylon 80µm filters (#NY8002500) using
25mm Filter Holders (Pall Corp, #4320) to remove tissue
debris. Seventy microliters of the crude filtered homogenate was
aliquoted into pre-TOT labeled tubes and set aside. The saved
pre-TOT aliquot was mixed with 70 µL dH20 and 23 µL PBS
and passed through a 27 ½ gauge needle three times to prepare
the total extract.
To prepare filtered CYT and SYN fractions, the remaining
crude 80µm filtered homogenate was passed through 5µm
Supor membrane filters (Pall Corp, #4650) along with 300 µL
of Buffer A to filter out large organelles and nuclei; this filtrate
was centrifuged at 1,000 × g for 10min at 4◦C and supernatant
was transferred into pre-CYT tubes. The pellet was washed once
with Buffer A and centrifuged at 1,000 × g for 10min at 4◦C
to generate the SYN pellet. The SYN pellet was resuspended
in either 70 µL of Buffer B (PBS, 1.5% SDS, and 2mM DTT)
or 70 µL of PBS plus protease inhibitor. Half of the pre-CYT
supernatant was clarified as previously described (Tai et al., 2012)
via ultra centrifugation at 100,000× g for 1 h at 4◦C to obtain the
Ultra-CYT sample. The other half of the pre-CYT supernatant
was centrifuged at 10,000 × g for 15min at 4◦C to remove any
remaining debris and obtain the CYT samples.
Statistical Analysis
The data herein were analyzed for statistical significance using
the graphing program GraphPad Prism 6. Data were analyzed
for normal distribution where possible using the Shapiro-Wilks
test. For parametric analyses, two-tailed Student t-test, One-
way ANOVA with Sidak post-hocmultiple comparisons analysis,
and Two-way repeated measures ANOVA with Sidak post-
hoc multiple comparisons analysis was performed. For non-
parametric analyses, two-tailed Mann-Whitney and Kruskal-
Wallis with Dunnett post-hoc multiple comparisons analysis was
performed. For correlation analysis, Spearman correlation was
performed and the line-of-best fit generated by linear regression
analysis. Individual data points represent individual human
cases. Data presented as Mean ± standard error of the mean
(SEM).
RESULTS
Brain Regions With Rare Tau Pathology
Exhibit High Levels of Tau Seeding
The presence of tau seeding as measured using the tau TauRD-
P301S-CFP/YFP in vitro biosensor (Holmes et al., 2014) has
previously shown an association with the presence of tau
pathology, both in tau transgenic mice (Holmes et al., 2014;
DeVos et al., 2017) and in human brains (Furman et al., 2017;
Nicholls et al., 2017; Nobuhara et al., 2017). Interestingly, tau
seeding has also been reported in tissues—both in mice and
in human brain lysate—where overt tau pathology has not yet
developed or is rare (Holmes et al., 2014; Furman et al., 2017),
suggesting that some amount of tau aggregates exist in a brain
region before they accumulate to a point of filling the neuronal
somatodendritic compartment and are abundantly detected by
tau IHC. We analyzed the entorhinal cortex (EC) (first region
to be impacted by tau pathology) and the primary visual cortex
(V1) (last region to be impacted by tau pathology) in cases with
rare NFTs in the EC (Low Braak) and cases with extensive NFTs
throughout all regions along the Braak Tau Pathway, including
EC and V1 (High Braak). Using the cerebellar vermis from the
High Braak brains as an unaffected control region, samples were
run on a western blot for phosphorylated tau (antibody PHF-1;
epitope 396/404), since the presence of hyperphosphorylated tau
has previously indicated the presence of tau seeding (Holmes
et al., 2014; DeVos et al., 2017; Nobuhara et al., 2017). Predictably
in a High Braak brain, phospho-tau could be detected in both
the EC and V1 (Figure 1A). In a Low Braak brain, while there
is only rare tau NFTs in the EC observed by IHC, phospho-tau
could still be detected in the EC, though not in the V1, perhaps
reflecting aberrant tau phosphorylation prior to the development
of mild tau pathology at the site of AD tau pathology initiation
(Figure 1A). When applied to the tau seeding assay, the EC
lysate from the Low Braak cases showed a significant increase
in tau seeding activity with no seeding being detected in the
V1 Low Braak lysate (Figures 1B,C). Both the EC and V1
lysates from the High Braak cases showed significant tau seeding.
While the presence of PHF-1 tau here predicted the presence
of seeding, it did not correlate with the amount of seeding
activity.
To then test whether the lack of seeding in the cerebellar
samples was indeed due to a lack of aggregated tau and not due
to less total tau protein, we measured total human tau levels
in the cerebellar and EC samples of Braak VI cases and added
equal tau amounts to the seeding assay. With this total tau
normalization, there was still no detectable seeding activity in
the cerebellar samples while all EC samples showed detectable
seeding (Supplementary Figure 2). Similar to what has been
previously reported, these data show that substantial tau seeding
can be detected in both the presence of extensive tau pathology
as well as when there are only the rare detectable NFTs.
Tau Seeding Is Detected in Brain Regions
Along the Braak Tau Pathway That Are Not
Yet Impacted by Tau Pathology
In the Low Braak cases, tau seeding could be detected in the
EC, but not the V1 (Figure 1). Since tau pathology consistently
begins in the EC in human AD brains, we hypothesized that
tau seeding in the EC of Low Braak patients is a predictor of
further developing tau pathology. To explore this hypothesis, we
collected a series of tissues along the Braak Tau Pathway in a
series of human cases (Table 1) ranging from Braak I to Braak
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FIGURE 1 | Tau seeding activity can be found in brain regions with rare tau pathology. (A) Representative western blot for total tau and PHF-1 phospho-tau of the
cerebellum (Cb), entorhinal cortex (EC), and primary visual cortex (V1) of Braak cases with rare NFTs in the EC (Low Braak; LB) and Braak cases with extensive NFTs
across the brain (High Braak; HB). Dashed black line indicates discontinuous lanes on the blot. (B) Tau seeding as measured on the flow cytometer in the
HEK239-TauRD-CFP/YFP seeding cells can be detected in the EC of Low Braak cases despite there being only rare tau pathology. (C) Representative photos of
induced tau aggregates in the HEK239-TauRD-CFP/YFP cells. One-way ANOVA, Sidak post-hoc multiple comparisons. *p < 0.05, **p < 0.01. Individual dots
represent individual human cases. Mean ± SEM.
VI (Figure 2). Each region collected represents an area that tau
pathology would be found in the staging of human brains for
Braak status. The regions and corresponding Braak stage are
as follows: Braak I, EC; Braak II, Hippocampus (Hp); Braak
III, Posterior Parahippocampal Gyrus (PPG); Braak IV, Anterior
Cingulate Cortex (AC); Braak V, Visual Association Cortex (VA);
Braak VI, Primary Visual Cortex (V1). Brains were staged based
on the furthest region tau pathology had reached; a Braak IV
brain had at least mild tau deposition in only the EC, Hp, PPG,
and AC. The cerebellar vermis was also collected from all brains
as an unaffected control brain region.
All brain regions from the human cases were dounce
homogenized in 1X PBS and the supernatant from a 3,000 × g
spin collected. This lysate was then applied to the tau seeding
assay to measure tau seeding along the Braak Tau Pathway. As
an initial assessment of tau seeding across the different tau Braak
stages, tau seeding across all brain regions for each case was
aggregated into a single “total brain” seeding value and plotted
against the Braak stage for that brain (Figure 3A). A significant
direct correlation between tau seeding and Braak stage emerged,
similar to what others have seen in human tissue (Furman et al.,
2017).
The main advantage to collecting all regions of the Braak
pathway, however, lies in being able to look one region past
where tau pathology has been identified.When tau seeding across
all regions of all cases is plotted, it becomes evident that tau
seeding is detectable in brain regions were tau pathology has
not yet reached (Figure 3B). This tau seeding often precedes
tau pathology by one region along the Braak Tau Pathway
(Figure 3C). While the group mean results are in accordance
with previous reports that tau seeding can be detected in brain
regions that, according to their tau Braak status, do not yet have
overt tau pathology (Furman et al., 2017), the patient to patient
variability is worth noting. Even within a single tau Braak stage,
not all cases follow the same tau seeding pattern, highlighting
the complex heterogeneity of Alzheimer’s disease. Even with this
variability, these data cumulatively suggest that tau aggregates
develop within a defined brain region and, while accumulating
over time to a point of being detectable by IHC, simultaneously
traverse along axons to the next synaptically connected region
along the Braak Tau Pathway.
Brain Regions Consisting of Almost
Exclusively Neuronal Axons Exhibit Tau
Seeding Activity
For seed competent tau aggregates to move along the Braak Tau
Pathway transneuronally, they must at some point exist in the
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FIGURE 2 | Tau Pathology along the Tau Braak Pathway. (A) Brain regions collected from human cases ranging from Braak I–Braak VI (Table 1). Each region
corresponds to a region in the Braak Tau Pathway. They are as follows: Braak I, entorhinal cortex; Braak II, hippocampus; Braak III, posterior parahippocampal gyrus;
Braak IV, anterior cingulate cortex; Braak V, visual association area; Braak VI, primary visual cortex. Additionally, the cerebellar vermis was collected as an unaffected
control region. (B) Representative tau IHC photos of tau pathology in brain regions along the Braak Tau Pathway in different Braak staged cases. The
Occipitotemporal Gyrus and Posterior Parahippocampal Gyrus can both be use for Braak III staging.
axonal compartment of the neuron. To test this idea, we collected
two regions of the human brain that are enriched for neuronal
axons and lack neuronal cell bodies: the frontal white matter
tracts (Fwhite) and the optic nerve (ON). A decrease in NeuN—
a pan-neuronal marker that is expressed almost exclusively in
the neuronal cell body and nucleus—is seen in both the ON
and the Fwhite lysates as compared to the neuronal cell body
rich adjacent Frontal gray matter (Fgray) (Figure 4A). To ensure
overt tau pathology was in the Fgray matter, Braak V/VI cases
were chosen. High levels of phospho-tau were detected in the
Fgray matter and, interestingly, a small amount of phospho-
tau could also be identified in the Fwhite matter despite there
being very few neuronal cell bodies and no NFTs in the white
matter tracts (Figure 4B). The Fgray matter was run on the
tau seeding assay and indeed, tau seeding was detected in all
cases (Figure 4C). To then test whether the Fwhite matter also
contained seed competent tau despite being relatively devoid
of neuronal cell bodies, the Fwhite lysate was applied to the
same seeding assay and a significant amount of tau seeding was
detectable (Figure 4D). It is interesting to point out that while
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FIGURE 3 | Tau seeding activity precedes tau pathology along the Braak Tau Pathway. (A) Lysates along the Braak Tau Pathway for cases ranging from Braak I to
Braak VI were all run on the tau seeding assay. Tau seeding values across the all brain regions analyzed were aggregated into a single value for each case and plotted
against the Braak status of that brain. A significant direct correlation emerged, whereby as the Braak stage of the brain increases, so does the tau seeding activity
across the whole brain. Spearman correlation. (B) Heatmap of tau seeding across the brain regions in the Braak Tau Pathway in human brains ranging from Braak I to
Braak VI. Regions are organized left to right according to the progression of tau pathology throughout the course of AD; the EC is the first region to be impacted by
tau pathology and the V1 is the last region. (C) Plots broken up based on the Braak stage of the brains. When compared to the unaffected cerebellum, tau seeding
can be detected at least one region past where tau pathology is detected. Kruskal-Wallis test, Dunn’s post-hoc multiple comparisons. #p < 0.01, *p < 0.05,
**p < 0.01. Individual dots represent individual human cases. Mean ± SEM.
the total tau levels between the Fgray and Fwhite matter are similar,
there is much higher levels of seeding activity in the Fgray matter.
This could reflect a number of different possibilities, such as the
majority of the seed competent tau exists in the somatodendritic
region of the neuron and is the source of axonally trafficked
aggregated tau or, alternatively, axonal tau can misfold directly
in the axon but to a much lesser extent than somatodendritic
tau.
While there are significantly less neuronal cell bodies in the
Fwhite matter as compared to the Fgray matter, up to 1% of
the cell bodies in the white matter are neuronal (García-Marín
et al., 2010). The ON, however, is a unique part of the human
central nervous system in that it is not only completely devoid
of neuronal cell bodies, but the axonal projections in the ON
derive from the retinal ganglion cells, a neuronal cell type that
does not develop NFTs (Blanks et al., 1989; Ho et al., 2014),
and synapses onto the lateral geniculate nucleus. Interestingly, in
Braak V/VI cases, we found detectable levels of both phospho-
tau (Figure 4E) and tau seeding (Figure 4F) in the ONs (but not
in Braak 0-II cases), highlighting the notion that seed competent
tau aggregates exist in other neuronal compartments outside of
the neuronal cell body. It is unclear from this assay if the tau
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FIGURE 4 | Tau seeding activity is found in axonally-rich brain regions with few to no neuronal cell bodies. (A) Representative western blot for pan-neuronal nuclei
marker NeuN in optic nerve (ON), frontal cortex white matter (Fwhite), and frontal cortex gray matter (Fgray) from Braak V/VI human AD cases. Dashed black line
indicates discontinuous lanes on the blot. (B) Western blot of total and PHF1 phospho-tau in Fwhite and Fgray matter samples, demonstrating that a small amount of
phospho-tau exists in the Fwhite matter, despite there being almost no neuronal cell bodies. (C,D) Tau seeding is detected in both the Fgray lysates (C) and
corresponding Fwhite lysates (D). The Fgray and Fwhite matter samples were run at the same time on the seeding assay. (E) Western Blot of total and PHF1
phospho-tau in control and Braak V/VI AD optic nerves. Phopsho-tau is more readily detected in AD optic nerves. (F) Tau seeding can be registered in optic nerve
samples from AD human cases, despite there being no neuronal cell bodies. Two-tailed student’s t-test. *p < 0.05, **p < 0.01. Individual dots represent individual
human cases. Mean ± SEM.
aggregates derive from the RGCs or the synaptically connected
LGN. Nonetheless, tau seeding is detectable along the axons in
the ON.
Tau Seeding Activity Is Enriched in
Synapses Along the Braak Tau Pathway
Tau seeding can be detected in regions of the human brain
devoid of neuronal cell bodies and enriched for axons. For
aggregates of tau to propagate transneuronally, one proposed
mechanism is the movement of aggregates from one neuron
to the next across synapses. We have previously detected an
increase in phosphorylated oligomeric tau in the synaptosome
fraction of AD brain lysate when compared to control tissue
(Tai et al., 2012, 2014; Perez-Nievas et al., 2013). To expand on
these results and test whether aggregates of tau can be detected
in synapses along the Braak Tau Pathway, the cytosolic and
synaptosome fractions were isolated (Supplementary Figure 1)
in three different brain regions from early AD (Braak I–
III) and late AD (Braak V–VI) cases (Figure 5A). The tau
NFT burden reveals mild/moderate levels of NFTs in the
first three regions of the Tau Braak Pathway of the Braak
I–III group, while the Braak V–VI cases show much more
severe NFT burden in the earlier Braak Tau Pathway regions
that tapers off in later regions (Figure 5A). Synaptosome and
cytosolic fractions were prepped and when run on western
blot, the synaptic-specific protein post-synaptic density 95
(PSD-95) was heavily enriched in the synaptic vs. cytosolic
fraction (Figure 5B), demonstrating the efficacy of the synaptic
enrichment preparation. The cytosolic and synaptic fractions
were run on western blot and probed for both total tau and
phospho-tau (Figure 5C). While the levels of total tau remained
similar across the different cases and fractions, there was a
visible increase in the phospho-tau:total tau ratio in the synaptic
fractions when compared to the cytosolic fraction from the same
case (Figure 5C).
We next ran the cytosolic and synaptic fractions from all
cases across all regions on the tau seeding assay to measure the
amount of tau seeding activity in the cytosol and synapses along
the Braak Tau Pathway in both early and late AD conditions
(Figure 5D). In the hippocampus, one of the earlier regions to
be impacted by tau pathology, there was a significant enrichment
of tau seeding in the synapses as compared to the cytosol in
the Braak I–III cases, though interestingly, not in the more
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FIGURE 5 | Tau seeding activity is enriched in synapses along the Braak Tau Pathway. (A) Schematic of the Braak Tau Pathway. The cytosol and synaptosome
fractions were isolated from the Hippocampus (Hp), Anterior Cingulate (AC), and Primary Visual cortex (V1) of human cases. Cases were broken up into early AD,
Braak I–III—or late AD, Braak V–VI. The tau neurofibrillary tangle (NFT) burden for each brain region along the pathway shows not only a difference in how far tau
pathology has reached, but also the NFT burden level—mild, moderate, or severe— in those regions. (B) Representative western blot showing the enrichment of
PSD-95 (a synaptic protein) in the isolated synaptosome fraction compared to the cytosolic fraction. Actin was used as a loading control. (C) Cytosolic and
synaptosome fractions from Braak I–III cases were run on western blot for total tau (left) and PHF1 phospho-tau. (D) All cytosolic and synaptosome fractions were run
on the tau seeding assay and the cytosolic and synaptic tau seeding levels plotted across the Braak Tau Pathway for both the Braak I–III and Braak V–VI groups. The
lines between the cytosolic and synaptic seeding values represent the same case. Two-way repeated measures ANOVA, Sidak post-hoc multiple comparisons.
(E) The ratio of PHF1:Total tau on the western blot for all samples was plotted against the tau seeding levels of all the same samples, yielding a significant direct
correlation. Overlaid is the line of best fit and the 95% confidence interval bands determined by linear regression. Spearman correlation. *p < 0.05, ****p < 0.0001.
Individual dots represent individual human lysate samples.
heavily impacted Braak V–VI cases. In the later regions in the
Braak Tau Pathway—the Anterior Cingulate and Primary Visual
Cortex—, there was almost no seeding in the early AD Braak I–
III cases. However, in the late AD cases, we observed the same
phenomenon as in the early AD hippocampus—a significant
increase in the seeding activity in the synapses as compared
to the cytosolic fraction. From these data, it suggests that in
brain regions with mild to moderate tau pathology, there is an
enrichment in phosphorylated seed competent tau species in the
synapses, lending support to the idea of tau aggregates moving
transneuronally through the human AD brain along synaptically
connected brain regions.
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DISCUSSION
In keeping with previous in vivo and human literature (Holmes
et al., 2014; Furman et al., 2017), we have recapitulated the
finding that tau seeding—i.e., the ability of an aggregate of
tau to recruit naïve monomeric tau—can be detected before
extensive visible tau pathology (Figure 1). In fact, this seed
competent tau precedes tau pathology along the Braak Tau
Pathway by at least one region (Figures 2, 3). Further, tau seeding
can be detected in two axonally rich regions of the human
brain that are devoid of neuronal cell bodies (frontal white
matter tracts and optic nerve), suggesting that aggregates of
tau can move along axons as a possible mode of transmission
through the brain (Figure 4), a mechanism that has been
shown to be feasible in vitro (Wu et al., 2013; Takeda et al.,
2015). Finally, we demonstrated in regions of the human AD
brain that are not yet substantially impacted by tau pathology
that tau seeding is significantly enriched in the synapses as
compared to the cytosol (Figure 5), further providing evidence
that tau aggregates can move along synaptically connected brain
regions as Alzheimer’s disease progresses through the human
brain.
It has long been known that tau pathology appears in human
AD brains in a very spatially consistent manner, starting in the
entorhinal cortex and ultimately culminating in the primary
visual cortex. These pathology data have laid the framework
for the theory that tau aggregates move through the brain
transneuronally along this pathologically defined Braak Tau
Pathway, ultimately resulting in overt tau pathology and neuronal
cell death along the same pathway. Numerous in vitro studies
have demonstrated cellular uptake of tau aggregates, the ability
of tau aggregates to recruit and template naïve monomeric
tau, and the fact that tau aggregates can be released from
neurons (Frost et al., 2009; Kfoury et al., 2012; Holmes et al.,
2013; Wu et al., 2013; Sanders et al., 2014; Takeda et al.,
2015; Nobuhara et al., 2017). Further, tau aggregates can be
seen moving both anterograde and retrograde along axons (Wu
et al., 2013). Expounding on these in vitro studies, several
groups have now reported that this same phenomenon can occur
in vivo, both in genetic models that drive tau expression in the
entorhinal cortex (de Calignon et al., 2012; Liu et al., 2012),
as well as injection models that show both the recruitment
of endogenous tau and spread of aggregates to synaptically
connected brain regions (Clavaguera et al., 2009, 2013; Iba et al.,
2013; Ahmed et al., 2014; Dujardin et al., 2014; Sanders et al.,
2014; Stancu et al., 2015; Narasimhan et al., 2017). These results
set the stage for investigating the movement of tau aggregates
through the human brain along the pathologically defined Braak
Tau Pathway. It was recently demonstrated that tau seeding
can be detected in the human AD brain before the onset of
tau pathology (Furman et al., 2017), a phenomenon that was
previously seen in tau transgenic mice (Holmes et al., 2014).
Our results herein recapitulate these data by identifying seed
competent tau in brain regions along the Braak Tau Pathway
that do not yet have overt tau IHC pathology. We further
analyzed axonally rich regions of the human brain almost or
completely devoid of neuronal cell bodies—frontal white matter
and optic nerve, respectively—and observed seed competent
tau existing outside of the neuronal soma compartment. These
regions of the human brain are densely comprised of axons,
though it should be noted that they also contain glia cells,
including oligodendrocytes, astrocytes, and microglia. Microglia
have been shown in vivo to take up tau aggregates (Bolós
et al., 2015; Luo et al., 2015), though in AD white matter,
we do not see any pathological tau deposition. Glial cells
also have significantly less tau expression than neurons (Leyns
and Holtzman, 2017) and thus, if they contain detectable tau
aggregates and seeding activity, the aggregates are likely coming
from neighboring neuronal axon projections where tau is much
more abundant.
One proposed method of tau aggregate transneuronal spread
is the synaptic release of tau aggregates that then get taken
up by the adjoined neuron. We and others have previously
shown that phosphorylated-tau oligomers are enriched in the
synapses of human AD brain tissue, as compared to control,
while total tau remains the same between the synaptic and
cytosolic fractions (Henkins et al., 2012; Tai et al., 2012, 2014;
Perez-Nievas et al., 2013; Sokolow et al., 2015; Zhou et al.,
2017). In these studies, oligomeric tau could be detected in both
the pre-synaptic and post-synaptic particles as assessed by IHC
(Tai et al., 2014), though the synaptosome preparation used in
these past studies and our current work herein isolates both
pre- and post-synapses together. The isolation of both pre- and
post-synapses together, while an important first step, invites
futures studies looking at the seeding levels specifically in pre-
and post-synaptic fractions. This would allow for the further
dissection of whether tau aggregates can exist not only in post-
synapses as is predicted with the somatodendritic localization
of tau pathology, but also in the pre-synaptic compartment
which would further suggest a trans-synaptic mechanism of
propagation.
In addition to looking at both pre- and post-synapses together,
previous studies looking at tau oligomers in synaptic fractions
were generated using only one region. Our results using synaptic
and cytosolic fractions along three regions of the Braak Tau
Pathway not only recapitulated the increased ratio in pTau:Total
tau in the synaptic fractions, but also demonstrated for the
first time a significant increase in tau seeding at the synapse
in human brain tissue. Interestingly, we noted that in the
presence of severe NFTs, there was not a significant enrichment
of tau seeding in synapses, unlike regions with mild-moderate
NFT burden. This could be due to a number of reasons. In
brain regions heavily impacted by NFTs, there is a substantial
increase in cytosolic tau accumulation as seen by tau pathology
staining, reflecting the re-organization of tau to the soma. This
reorganization would likely increase the amounts of cytosolic
tau seeds and result in more similar tau seeding value between
cytosol and synapse fractions. There is also synaptic loss that
corresponds to the presence and level of tau pathology (Scheff
et al., 2007; Yoshiyama et al., 2007; Polydoro et al., 2014; Spires-
Jones and Hyman, 2014; Pickett et al., 2017), such that tau
aggregates may not be able to spread via synaptic connections
to the same degree if there are less overall synapses. On the
converse, in those regions with only mild to moderate NFT
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burden that have not yet experienced the same level of cytosolic
tau pathology or synapse loss, tau aggregates can still propagate
across synapses (Calafate et al., 2015), thus resulting in the
local synaptic enrichment of tau seeding. In the rTgTauEC
propagation mouse model (de Calignon et al., 2012; Liu et al.,
2012), this same phenomenon was observed, whereby human tau
spread from the EC to the synaptically connected dentate gyrus
early in the course of disease (Pickett et al., 2017). Importantly,
this spread of human tau occurred before the advent of synapse
and neuronal loss, suggesting that the spread of tau between
adjoining neurons is not simply due to the degeneration of axon
terminals, but instead is an active early event in the disease
progression.
The data generated here and in previous literature looking
at tau seeding levels in the human brain have been done in
a cross-sectional manner from frozen autopsy tissue. Tracking
tau aggregates traversing from one brain region to another in a
living person is not yet feasible. However, while more crude, the
presence of tau NFTs can be analyzed longitudinally in the living
human brain using tau positron emission tomography (PET)
imaging (Newberg et al., 2002). When coupled with Amyloid-
beta (Aβ) Pittsburg compound B (PiB) PET (Klunk et al., 2004)
and fluorodeoxyglucose (FDG)-PET imaging (Newberg et al.,
2002), a picture of the spatial and temporal development of
tau and amyloid pathologies emerges, helping illuminate how
each pathology relates to cell loss as the disease progresses.
In living human AD patients, it has now been demonstrated
that the spatial and temporal retention of the Tau PET ligand
corresponds well with Braak staging of NFT tau pathology
(Ossenkoppele et al., 2016; Schöll et al., 2016; Hoenig et al.,
2018). When the second major AD pathology—Aβ plaques—
is measured in the same patients, the deposition of Aβ and
tau as measured by PET show distinct patterns throughout the
AD brain (Sepulcre et al., 2016) with tau pathology showing a
more direct correlation with neural network functional decline,
cortical atrophy, and cognitive decline (Ishiki et al., 2015;
Ossenkoppele et al., 2016; Schöll et al., 2016; Hoenig et al.,
2018). These PET data not only reaffirm what the field has
long seen with tau IHC, but also set the stage to monitor
the progression of tau pathology along the Braak Tau Pathway
as new tau-based therapeutics are brought to the human
clinic.
It should be noted that the biosensor cell line used throughout
this study, while having been previously characterized, is an
artificial in vitro system with the repeat domain of tau containing
the P301S point mutation (Holmes et al., 2014; Furman
et al., 2015, 2017). In our studies here, we used the cells in
conjunction with a lipofectamine treatment purely as a tool
to better understand the total amount of seed-competent tau
aggregates in the samples tested. Studies have shown that AD
derived tau can induce seeding in this assay despite the P301S
mutation (Holmes et al., 2014; Furman et al., 2017). Further,
lipofectamine was used in our studies as we wanted to know
the full extent of seed competent tau in the lysates and to
avoid the additional variable of cellular uptake. Importantly,
while this study helps demonstrate that tau seeding activity can
exist in non-pathology containing regions along the pre-defined
Braak Tau Pathway, it should also be noted that the seeding
data herein do not provide information as to the potency
of each tau aggregate—e.g. how efficient an aggregate of tau
can be taken up by a cell and how much seeding each tau
aggregate can induce. Future studies that look at treating
neurons without lipofectamine and/or normalizing to total or
phosphorylated levels of tau will help get at some of these other
questions surrounding tau seeding activity from humanADbrain
lysate.
Knowing that the presence of NFTs is in direct correlation
with neuronal death and that tau aggregates appear to
propagate through the brain transneuronally, several tau directed
therapeutics have emerged for the treatment of AD. In keeping
with the idea that tau aggregates move across synapses, one
possible treatment is tau immunotherapy—as tau aggregates are
released from a neuron, the aggregates can be captured by an
antibody and cleared before they can be taken up by the adjoining
neuron. This therapy has been shown both in vitro and in vivo
to be successful at preventing both tau pathology formation and
propagation (Boimel et al., 2010; Bi et al., 2011; Yanamandra et al.,
2013; Castillo-Carranza et al., 2014; Ittner et al., 2015; Nicholls
et al., 2017; Nobuhara et al., 2017). Based on these successful
studies, tau immunotherapy has been taken to the human clinic
by multiple groups for those with early AD (NCT02880956,
NCT03289143, NCT03056729). Interestingly, not all epitopes
of tau work as well at clearing the seed competent portion
of tau pathology (Yanamandra et al., 2013; Nobuhara et al.,
2017). To design a tau antibody that has the best chance of
preventing pathological tau propagation, the data herein suggest
that screening tau antibodies against the synaptic seed relevant
tau species may help generate a tau immunotherapy that is
unique to the species of tau responsible for AD progression.
Other therapies, such as preventing the subsequent uptake
(Holmes et al., 2014) or release of tau aggregates, could, based
on these data, help slow or prevent the spread of tau aggregates
and thus clinical progression of human AD.
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Supplementary Figure 1 | Synaptosome protocol outline. (A) Schematic of
synaptosome prep protocol and different conditions tested. (B) Total tau and
phospho PHF1 tau blots, demonstrating that boiling the preps did not impact the
tau banding patterns. (C) Total and phospho PHF1 tau blots, demonstrating that
ultra-centrifugation of the cytosolic fraction lead to a large decrease in phospho
PHF1 tau, while spinning the cytosolic fraction at the same speed as the
synaptosome fraction retained phospho PHF1 tau in the sample.
Supplementary Figure 2 | Tau seeding normalized to total tau levels. Biosensor
cells treated with lysate normalized to 40 ng/mL total tau. Tau seeding was
normalized to cells treated with no lysate (NT). After normalizing to total tau,
cerebellum (Cblm) lysate from High Braak cases did not induce tau seeding
activity while the entorhinal cortex (EC) lysate shows significantly more seeding
compared to both NT and Cblm treated cells. One-way ANOVA, Sidak post-hoc
multiple comparisons test. ∗p < 0.05. Individual dots represent individual human
cases. Mean ± SEM.
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